-
October 25, 2012
Elan Corporation's (ELN) loss of 5 cents per share (excluding special items) for the second quarter of 2012 was ...
-
October 12, 2012
Elan Corporation (ELN) and partner Biogen Idec (BIIB) recently presented data from 11 company-sponsored Tysabri ...
-
October 12, 2012
We recently upgraded Alkermes plc (ALKS) to Outperform from Neutral with a target price of $21.00. Our long term ...
-
October 10, 2012
PDL BioPharma, Inc. (PDLI) and AxoGen, Inc. (AXGN) recently completed a structured financing transaction. As per the ...
-
October 09, 2012
Shares of Eli Lilly and Company (LLY) reached a 52-week high of $50.94 on Monday with the company reporting full ...
-
October 01, 2012
Recently, Alkermes plc (ALKS) announced the successful completion of the refinancing of its previously outstanding ...
-
September 22, 2012
A look at four sectors that led the market in the spring shows us not only which industry groups have long-term ...
-
September 18, 2012
We are moving back to a Neutral recommendation on Alkermes plc (ALKS) as we believe the stock is fairly valued at ...
-
September 07, 2012
PDL BioPharma Inc. (PDLI) recently announced that it expects to generate third quarter 2012 royalty revenues of $85 ...
-
September 06, 2012
Elan Corporation (ELN) recently initiated a phase II placebo-controlled, safety and efficacy study with oral ...
-
August 31, 2012
The market is on the rise this morning. The Nasdaq has climbed 0.8%; the S&P 500 is up 0.8%; and the Dow has risen ...
-
August 30, 2012
The market is currently down, with the Nasdaq slipping 0.9%, the S&P 500 down 0.7% and the Dow declining 0.7%. The ...
-
August 28, 2012
Eli Lilly and Company (LLY) recently announced much awaited top-line results on Alzheimer's disease candidate, ...
-
August 14, 2012
Elan Corporation (ELN) recently announced its decision to split into two separate publicly traded companies. The ...
-
August 13, 2012
The market is having a bad day so far. The Nasdaq has declined 0.3%; the S&P 500 is down 0.4%; and the Dow has ...
-
August 07, 2012
Pfizer, Inc. (PFE) recently announced disappointing late-stage results on intravenous (IV) bapineuzumab. ...
-
August 07, 2012
The market is having a good day so far: the Nasdaq has climbed 0.8%; the S&P 500 is up 0.7%; and the Dow has risen ...
-
August 06, 2012
PDL BioPharma Inc. (PDLI) posted second-quarter earnings of 53 cents per share, above the year-ago figure of 39 ...
-
August 01, 2012
Acorda Therapeutics Inc. (ACOR) reported second quarter earnings (including share-based compensation charges but ...
-
July 31, 2012
Alkermes plc (ALKS) reported earnings of 28 cents per share (including depreciation and stock-based compensation ...
